Zoladex Depot

Zoladex 3.6mg Depot (Goserelin Acetate) is an antitumor hormone drug that is used in such cases as hormone-dependent prostate cancer, hormone-dependent breast cancer in women during the reproductive period or in perimenopause, endometriosis, uterine fibroids (in combination with surgical treatment), inhibition pituitary function in the preparation of stimulation of superovulation in the framework of the IVF program (in vitro fertilization), the need for preliminary thinning of the endometrium before surgery.

Always follow your doctor`s instructions when using Zoladex 3.6mg Depot (Goserelin Acetate) to get the safest and most effective results from treatment. The typical dosage is 1 injection every 28 days. Zoladex 3.6mg Depot (Goserelin Acetate) should be carefully administered to the anterior abdominal wall due to the proximity of the abdominal aorta and its branches.

Local anesthetic is permitted, but in most cases it is not needed.

Always ask your doctor any questions you have about using the medication to ensure the correct administration.

The use of Zoladex 3.6mg Depot (Goserelin Acetate) may cause side effects in some patients including:

• dizziness, headache
• sleep disturbance
• excessive fatigue or weakness
• anxiety, depression
• increase in blood pressure
• arrhythmia
• anemia
• upper respiratory tract infection
• decreased appetite, nausea, vomiting
• constipation or diarrhea
• skin rash
• sweating enhancement
• decreased potency
• amenorrhea
• decrease in bone density and bone mass

Contact your doctor immediately if you experience any serious or worrying symptoms!

Zoladex 3.6mg Depot (Goserelin Acetate) is contraindicated in pregnancy. Zoladex 3.6mg Depot (Goserelin Acetate) may have a harmful embryonic effect when used by pregnant women. In women of childbearing age, pregnancy should be excluded before starting therapy. Women need to use non-hormonal methods for contraception during treatment with goserelin and within 12 weeks after its cancellation. If goserelin is used during pregnancy or if pregnancy has occurred during goserelin therapy, the patient should be warned of potential harm to the fetus and the risk of spontaneous miscarriage.

Breastfeeding should be discontinued during treatment.